News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Video
16 March 2026

EIFO’s CEO travels from professional pessimist to reluctant...

Is the Danish export credit agency punching under its weight? EIFO CEO Peder Lundquist discusses how the ECA is evolving its unique model post-merger, upping its emphasis on...

Perspective
23 March 2026

Export and commodity finance volumes balloon in 2025 as...

TXF has published its 2025 data reports for the export and commodity finance industries. Borrowers are raising bigger deals as geopolitical pressures increase supply chain...